ClinicalTrials.gg
RecruitingNCT05180994Updated Apr 27, 2026

Topical Infliximab in Eyes With Penetrating Keratoplasty

A Phase 1/2 interventional study of Topical infliximab and No topical infliximab in Glaucoma Following Surgery, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Glaucoma with a site in Canada — 17 open to participants now, 21 under way, 1 of them phase 3. Glaucoma · Canada.

Planned enrollment
40th of 68
50 · median 62
Started
2022
with 2 others
Phase 1/2
Only one
of the 85
Primary completion
2027-03
later than 10 of 20 live
Registered
75th of 85
by date
Lead sponsor
7 of 85
Centre hospitalier de l'Université de Montréal (CHUM)

Among the 85 studies in Glaucoma with a site in Canada, this one is the 40th largest by planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2022, is the only one in phase 1/2, reaches primary completion later than 10 of the 20 other live ones, and was the 75th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

17 of the 85 studies in Glaucoma with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Glaucoma with a site in Canada, or all of them as a file.
02

Study summary

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

Read the detailed description

This is a prospective, multicenter, double-arm open clinical trial of 50 patients receiving a first penetrating keratoplasty (PKP) surgery, recruited to receive infliximab drops post-operatively.

The current study aims to evaluate whether using topical infliximab 10mg/ml eye drops is safe and efficient to prevent the emergence of glaucoma of inflammatory etiology in patients with PKP. This study is examining a new form of delivering infliximab (as eye drops instead of injections in the veins). 25 patients who will be undergoing PKP surgery will be recruited to receive infliximab drops as a part of this study.

The research hypothesis is that topical infliximab used during the PKP post-operative period will be safe, and could protect against the occurrence of glaucoma.

For comparison purposes, if some patients are not qualified to receive infliximab or should they refuse to receive infliximab, these patients will still be offered to follow the same follow-up schedule, questionnaires, examinations and non-invasive tests (excluding lab work), as patients who will be receiving infliximab. The number of patients in this control group will also be limited to 25 patients.

During the treatment period, patients in the interventional arm of the study will be receiving topical infliximab 10mg/ml eye drops four times per day, for a duration of 3 months. Patients will be monitored for another 3 months after cessation of the study drug. The total study duration for each patient will be 6 months.

Regarding statistical analysis, the primary and secondary outcomes of the study will be described, including : percentage of patients presenting with a thinning of mean retinal nerve fiber thickness measured using OCT (optical coherence tomography), with thinning in four quadrants (inferior, superior, nasal, temporal); proportion of patients without glaucoma over time; mean change in BCVA (best corrected visual acuity) compared to baseline BCVA; OSDI (Ocular Surface Disease Index) score evolution over time; quantification of ocular surface inflammation; quantification of anterior chamber inflammation; epithelial healing time; and incidence of epithelial keratitis.

Visual acuity values will be converted to LogMAR. Data will be presented as numbers and percentages for categorical variables, and as mean ± standard deviation for continuous variables. Comparison between experimental and comparison groups will be done using student's t test if distribution is parametric, and Mann-Whitney U test if distribution is non-parametric. The Kaplan-Meier curve will be used in order to illustrate the proportion of patients without glaucoma over time. An interim statistical analysis will be done once n=10 patients will have completed the full 6 months of study follow-up. A statistical significance level of α=0.05 will be used.

03

Conditions studied

  • Glaucoma Following Surgery

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 80 years;
  • First corneal transplant surgery;
  • Capable of providing ;
  • Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.

Exclusion criteria

Exclusion Criteria:

  • Active ocular infection;
  • Past corneal transplant (any technique);
  • Advanced glaucoma or macular disease;
  • Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or );
  • diagnosed in the past 5 years (any kind);
  • Demyelinating disease;
  • History or current diabetes mellitus (controlled or uncontrolled) or heart failure ( class III or IV);
  • Pregnancy or breastfeeding;
  • Allergy to infliximab or to a compound of its topical formulation;
  • Significant anomaly of complete blood count or hepatic enzymes;
  • Current or anterior use of anti-TNF-α medication or other anti-inflammatory biologics.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Topical infliximab following PKP surgery

    Additionally to standard post-operative regimen, patients who will be undergoing their first PKP surgery and who meet all inclusion and no exclusion criteria will be included in the experimental group. These patients will administer topical infliximab four times per day for 3 months.

    Drug: Topical infliximab

  • Active comparator
    No topical infliximab following PKP surgery

    Patients who will be undergoing their first PKP surgery, but who are not qualified to receive infliximab or who refuse to receive infliximab, will be included in the control group. These patients will only administer the standard post-operative regimen following their PKP surgery and will not administer topical infliximab. They will be followed with the same follow-up schedule, questionnaires, examinations and non-invasive tests (excluding lab work) as patients in the interventional group.

    Other: No topical infliximab

Interventions

  • DrugInfliximabStudies of InfliximabInfliximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.

    Also known as: Remicade

  • OtherNo topical infliximab

    No treatment with infliximab.

06

What researchers measure

Primary outcomes

  1. Complications associated to PKP surgery

    Number and type of complications associated to PKP surgery (graft loss, infectious keratitis, graft failure, corneal melting…)

    Time frame: 6 months

  2. Complications associated to infliximab use

    Number and type of complications associated with infliximab use (serious infections, allergic reactions, heart failure, blood problems, nervous system disorders, malignancies…; these complications have been observed with intravenous infliximab administration).

    Time frame: 6 months

Secondary outcomes

  1. Mean retinal nerve fiber thickness

    Percentage of patients presenting with a thinning of mean retinal nerve fiber thickness measured using OCT, with thinning in four quadrants (inferior, superior, nasal, temporal).

    Time frame: 6 months

  2. Occurrence of glaucoma

    Proportion of patients without glaucoma over time.

    Time frame: 6 months

  3. Best Corrected Visual Acuity (BCVA)

    Mean change in BCVA compared to baseline BCVA, measured using a Snellen chart.

    Time frame: 6 months

  4. Ocular surface symptoms

    Ocular surface symptoms as assessed by the Ocular Surface Disease Index (OSDI) questionnaire, ranging from 0 to 100, where a higher score indicates increased disease severity.

    Time frame: 6 months

  5. Quantification of ocular surface inflammation

    Conjunctival erythema on a scale of 0 to 4, where a higher score indicates increased disease severity.

    Time frame: 6 months

  6. Quantification of anterior chamber inflammation

    Quantification of anterior chamber inflammation according to the SUN definition (Standardization of Uveitis Nomenclature).

    Time frame: 6 months

  7. Epithelial healing time

    Number of days between surgery and absence of epithelial deficit.

    Time frame: 6 months

  8. Incidence of epithelial keratitis

    Incidence of epithelial keratitis assessed using the National Eye Institute Score (0-15).

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Mar 2027, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Jan 6, 2022
StartActual
May 1, 2022
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05180994
Collaborators
Fonds de recherche en ophtalmologie de l'Université de Montréal, Maisonneuve-Rosemont Hospital, Niagara Health System, Prism Eye Institute, Ottawa Hospital Research Institute
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
May 1, 2022
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Apr 27, 2026

Study contacts

Zobelle Tchouaga
Contact
zobelle.tchouaga.tongambou.chum@ssss.gouv.qc.ca
514 890-8000 ext. 11553
Marie-Claude Robert, MD
principal investigator · CHUM

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infliximab

Start the discussion